<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932267</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.110232</org_study_id>
    <nct_id>NCT02932267</nct_id>
  </id_info>
  <brief_title>Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne</brief_title>
  <acronym>EDeN</acronym>
  <official_title>Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide 2.5% in Moderate to Severe Acne in Dark Skin Phototype Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter open-label, prospective study in subjects with dark skin from one of
      the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American and with
      moderate to severe acne vulgaris on the face.

      All eligible subjects will receive Adapalene 0.3% - BPO 2.5% gel (Epiduo Forte/TactuPump
      Forte) once daily on whole face.

      The purpose of this trial is to evaluate subject reported outcomes with the combination of
      Adapalene 0.3% - BPO 2.5%, Epiduo Forte / TactuPump Forte gel, after 16 weeks of treatment of
      moderate to severe acne in dark skin phototypes (IV to VI).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject 's Overall satisfaction with study treatment via a satisfaction questionnaire</measure>
    <time_frame>At week 12</time_frame>
    <description>% of subjects satisfied to very satisfied with study treatment at week 12</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Adapalene / BPO gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adapalene 0.3% / BPO 2.5% gel, once daily in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene 0.3% / BPO 2.5% gel</intervention_name>
    <arm_group_label>Adapalene / BPO gel</arm_group_label>
    <other_name>Epiduo Forte / Tactupump gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with clinical diagnosis of moderate to severe facial acne vulgaris, defined
             by:

               1. Investigator's Global Assessment (IGA) score of 3 (Moderate) OR 4 (Severe ); and

               2. A minimum of 25-100 inflammatory lesions (papules and pustules); and

               3. A minimum of 30-150 non-inflammatory lesions (open and closed comedones) in total
                  (excluding the nose); and

               4. No more than two acne nodules (â‰¥ 1 cm),

          -  Subject with skin phototype IV to VI on Fitzpatrick skin phototype scale,

          -  Subjects from one of the 3 ethnic/race backgrounds: Asian, Latin American and
             Black/African-American,

        Exclusion Criteria:

          -  Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced
             acne, etc.), nodulo cystic acne, acne requiring systemic treatment,

          -  Subject with history of lupus, atopic dermatitis, perioral dermatitis,
             dermatomyositis, rosacea

          -  Female subject who is pregnant, lactating or planning a pregnancy during the trial,

          -  Subjects having received at least one of the following topical treatments on the
             treated area: Corticosteroids, antibiotics, benzoyl peroxide, azelaic acid, dapsone,
             hydroxyacids, Zinc containing treatments, antiseptics, other anti-inflammatory
             products or other acne treatments (2 weeks); Retinoids (4 weeks); Cosmetic/aesthetic
             procedures on the face (1 week); Wax epilation (2 weeks); Photodynamic therapy (6
             weeks); Laser therapy, microdermabrasion, deep chemical peel, plastic surgery for acne
             (3 months).

          -  Subjects having received at least one of the following systemic treatments:
             Corticosteroids, tetracyclines, other antibiotics (except penicillin) (1 month); Oral
             retinoids/isotretinoin/ anti-androgens / Cyproterone acetate / Chlormadinone acetate
             (6 months); Spironolactone/ Drospirenone (3 months); Immunomodulators (3 months) and
             Oral contraceptives/ oral dapsone for acne(1 month).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Farzaneh SIDOU</last_name>
    <phone>0033493957051</phone>
    <email>farzaneh.sidou@galderma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <country>Mauritius</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Mauritius</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne</keyword>
  <keyword>Dark skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

